Trends in uptake and impact of thermostable vaccines in Africa.

dc.contributor.authorKitui SK
dc.contributor.authorJuma E
dc.contributor.authorNdalama MT
dc.contributor.authorChilot D
dc.contributor.authorTolossa D
dc.contributor.authorWoldemedhin B
dc.contributor.authorMuzazu SGY
dc.contributor.authorDigamo K
dc.contributor.authorMungania J
dc.contributor.authorManyazewal T
dc.date.accessioned2025-09-17T10:25:49Z
dc.date.issued2025
dc.description.abstractVaccination in Africa faces significant challenges due to inadequate cold chain infrastructure, particularly in regions lacking reliable electricity. Approximately 80% of prequalified vaccines require cold chain systems to maintain their potency, which is often unfeasible in remote areas. Exposure to extreme temperatures can lead to a loss of vaccine potency, making it crucial to explore alternatives. Thermostable vaccines represent a technological advancement that addresses these challenges by eliminating the need for cold chain mechanisms during transport and storage. This narrative review analyzes trends in the uptake of thermostable vaccines and their impact across Africa. A total of 10 studies were reviewed, encompassing 14 African countries, revealing critical insights into the potential of thermostable vaccines to enhance immunization coverage in settings with limited access to traditional cold chain facilities. These vaccines, which maintain their efficacy even when exposed to higher temperatures for short periods, offer a promising solution to the logistical and economic hurdles of vaccine delivery in resource-limited settings.
dc.identifier.doi10.1177/25151355251341662
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/11916
dc.identifier.uri.pubmedhttps://pubmed.ncbi.nlm.nih.gov/40538680/
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, P. O. Box 9086, Addis Ababa, Ethiopia.
dc.relation.affiliationKenya National Public Health Laboratories-National Influenza Center, Nairobi, Kenya.
dc.relation.affiliationKenya Veterinary Vaccines Production Institute, Nairobi, Kenya.
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
dc.relation.affiliationUniversity of Gondar, Gondar, Ethiopia.
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
dc.relation.affiliationShenen Gibe General Hospital, Jimma, Ethiopia.
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
dc.relation.affiliationKotebe Metropolitan University, Addis Ababa, Ethiopia.
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
dc.relation.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
dc.relation.affiliationWachemo University, Hossana, Ethiopia.
dc.relation.affiliationKenyatta University, Nairobi, Kenya.
dc.relation.affiliationCenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
dc.sourceTherapeutic advances in vaccines and immunotherapy
dc.titleTrends in uptake and impact of thermostable vaccines in Africa.

Files

Collections